Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure

Larry D Cowgill, Katherine M. James, Julie K. Levy, Jeff K. Browne, Allan Miller, Robert T. Lobingier, Joan C. Egrie

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Objective - To test efficacy and safety of recombinant human erythropoietin (r-HuEPO) administration in dogs and cats with naturally developing chronic renal failure. Design - Case series. Animals - 6 client- owned dogs and 11 client-owned cats with chronic renal failure. Procedures - r-HuEPO was administered intravenously or subcutaneously. Erythropoietic effects were monitored by determining CBC, performing cytologic examination of bone marrow aspirates, and measuring serum iron concentration before and during treatment. Development of adverse effects was monitored by performing sequential clinical assessments, CBC, and serum biochemical tests and by measuring indirect blood pressure and anti-r-HuEPO antibody titers. Results - Administration of r-HuEPO increased RBC and reticulocyte counts, hemoglobin concentration, and Hct comparably in dogs and cats. Assessments of clinical well-being, including appetite, energy, weight gain, alertness, strength, and playfulness, were improved variably. Adverse effects, including anemia, anti- r-HuEPO antibody production, seizures, systemic hypertension, and iron deficiency, were demonstrated inconsistently in dogs and cats. Clinical Implications - Anemia contributes to clinical manifestations of chronic renal failure in dogs and cats. Administration of r-HuEPO has the potential to resolve anemia and improve clinical well-being. However, its administration poses risks of antibody production and adverse effects associated with correction of RBC mass. Use of r-HuEPO in dogs and cats requires conscientious assessment of risks and benefits until homologous forms of erythropoietin are available.

Original languageEnglish (US)
Pages (from-to)521-528
Number of pages8
JournalJournal of the American Veterinary Medical Association
Volume212
Issue number4
StatePublished - Feb 15 1998

Fingerprint

erythropoietin
renal failure
Erythropoietin
anemia
Renal Insufficiency
Anemia
Cats
Dogs
cats
dogs
Chronic Kidney Failure
adverse effects
antibody formation
Antibody Formation
erythrocytes
Iron
iron
Bone Marrow Examination
Reticulocyte Count
reticulocytes

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Cowgill, L. D., James, K. M., Levy, J. K., Browne, J. K., Miller, A., Lobingier, R. T., & Egrie, J. C. (1998). Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. Journal of the American Veterinary Medical Association, 212(4), 521-528.

Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. / Cowgill, Larry D; James, Katherine M.; Levy, Julie K.; Browne, Jeff K.; Miller, Allan; Lobingier, Robert T.; Egrie, Joan C.

In: Journal of the American Veterinary Medical Association, Vol. 212, No. 4, 15.02.1998, p. 521-528.

Research output: Contribution to journalArticle

Cowgill, LD, James, KM, Levy, JK, Browne, JK, Miller, A, Lobingier, RT & Egrie, JC 1998, 'Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure', Journal of the American Veterinary Medical Association, vol. 212, no. 4, pp. 521-528.
Cowgill, Larry D ; James, Katherine M. ; Levy, Julie K. ; Browne, Jeff K. ; Miller, Allan ; Lobingier, Robert T. ; Egrie, Joan C. / Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure. In: Journal of the American Veterinary Medical Association. 1998 ; Vol. 212, No. 4. pp. 521-528.
@article{1b8045b3994a460498cb09638eef100a,
title = "Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure",
abstract = "Objective - To test efficacy and safety of recombinant human erythropoietin (r-HuEPO) administration in dogs and cats with naturally developing chronic renal failure. Design - Case series. Animals - 6 client- owned dogs and 11 client-owned cats with chronic renal failure. Procedures - r-HuEPO was administered intravenously or subcutaneously. Erythropoietic effects were monitored by determining CBC, performing cytologic examination of bone marrow aspirates, and measuring serum iron concentration before and during treatment. Development of adverse effects was monitored by performing sequential clinical assessments, CBC, and serum biochemical tests and by measuring indirect blood pressure and anti-r-HuEPO antibody titers. Results - Administration of r-HuEPO increased RBC and reticulocyte counts, hemoglobin concentration, and Hct comparably in dogs and cats. Assessments of clinical well-being, including appetite, energy, weight gain, alertness, strength, and playfulness, were improved variably. Adverse effects, including anemia, anti- r-HuEPO antibody production, seizures, systemic hypertension, and iron deficiency, were demonstrated inconsistently in dogs and cats. Clinical Implications - Anemia contributes to clinical manifestations of chronic renal failure in dogs and cats. Administration of r-HuEPO has the potential to resolve anemia and improve clinical well-being. However, its administration poses risks of antibody production and adverse effects associated with correction of RBC mass. Use of r-HuEPO in dogs and cats requires conscientious assessment of risks and benefits until homologous forms of erythropoietin are available.",
author = "Cowgill, {Larry D} and James, {Katherine M.} and Levy, {Julie K.} and Browne, {Jeff K.} and Allan Miller and Lobingier, {Robert T.} and Egrie, {Joan C.}",
year = "1998",
month = "2",
day = "15",
language = "English (US)",
volume = "212",
pages = "521--528",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "4",

}

TY - JOUR

T1 - Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure

AU - Cowgill, Larry D

AU - James, Katherine M.

AU - Levy, Julie K.

AU - Browne, Jeff K.

AU - Miller, Allan

AU - Lobingier, Robert T.

AU - Egrie, Joan C.

PY - 1998/2/15

Y1 - 1998/2/15

N2 - Objective - To test efficacy and safety of recombinant human erythropoietin (r-HuEPO) administration in dogs and cats with naturally developing chronic renal failure. Design - Case series. Animals - 6 client- owned dogs and 11 client-owned cats with chronic renal failure. Procedures - r-HuEPO was administered intravenously or subcutaneously. Erythropoietic effects were monitored by determining CBC, performing cytologic examination of bone marrow aspirates, and measuring serum iron concentration before and during treatment. Development of adverse effects was monitored by performing sequential clinical assessments, CBC, and serum biochemical tests and by measuring indirect blood pressure and anti-r-HuEPO antibody titers. Results - Administration of r-HuEPO increased RBC and reticulocyte counts, hemoglobin concentration, and Hct comparably in dogs and cats. Assessments of clinical well-being, including appetite, energy, weight gain, alertness, strength, and playfulness, were improved variably. Adverse effects, including anemia, anti- r-HuEPO antibody production, seizures, systemic hypertension, and iron deficiency, were demonstrated inconsistently in dogs and cats. Clinical Implications - Anemia contributes to clinical manifestations of chronic renal failure in dogs and cats. Administration of r-HuEPO has the potential to resolve anemia and improve clinical well-being. However, its administration poses risks of antibody production and adverse effects associated with correction of RBC mass. Use of r-HuEPO in dogs and cats requires conscientious assessment of risks and benefits until homologous forms of erythropoietin are available.

AB - Objective - To test efficacy and safety of recombinant human erythropoietin (r-HuEPO) administration in dogs and cats with naturally developing chronic renal failure. Design - Case series. Animals - 6 client- owned dogs and 11 client-owned cats with chronic renal failure. Procedures - r-HuEPO was administered intravenously or subcutaneously. Erythropoietic effects were monitored by determining CBC, performing cytologic examination of bone marrow aspirates, and measuring serum iron concentration before and during treatment. Development of adverse effects was monitored by performing sequential clinical assessments, CBC, and serum biochemical tests and by measuring indirect blood pressure and anti-r-HuEPO antibody titers. Results - Administration of r-HuEPO increased RBC and reticulocyte counts, hemoglobin concentration, and Hct comparably in dogs and cats. Assessments of clinical well-being, including appetite, energy, weight gain, alertness, strength, and playfulness, were improved variably. Adverse effects, including anemia, anti- r-HuEPO antibody production, seizures, systemic hypertension, and iron deficiency, were demonstrated inconsistently in dogs and cats. Clinical Implications - Anemia contributes to clinical manifestations of chronic renal failure in dogs and cats. Administration of r-HuEPO has the potential to resolve anemia and improve clinical well-being. However, its administration poses risks of antibody production and adverse effects associated with correction of RBC mass. Use of r-HuEPO in dogs and cats requires conscientious assessment of risks and benefits until homologous forms of erythropoietin are available.

UR - http://www.scopus.com/inward/record.url?scp=0032519282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032519282&partnerID=8YFLogxK

M3 - Article

C2 - 9491159

AN - SCOPUS:0032519282

VL - 212

SP - 521

EP - 528

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 4

ER -